
Wednesday’s positive data for the eczema drug tralokinumab has given Leo Pharma a pat on the back for its relatively new gamble on biological medicines.
In three different late-stage studies, the company has achieved all primary and secondary effect goals, which is a result that research director Kim Kjøller calls ”incredibly strong”. Leo Pharma is now counting on using this data as a basis for approval applications to health authorities controlling the large markets in the new year.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app